CLINICAL MICROBIOLOGY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Size and Trends

Global clinical microbiology market is estimated to be valued at USD 4.98 Bn in 2024 and is expected to reach USD 7.19 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

To learn more about this report, request a free sample copy

Global clinical microbiology market is expected to witness positive growth during the forecast period, owing to factors such as  increasing prevalence of infectious diseases, growing awareness regarding diagnosis of infections, technological advancements in diagnostic techniques, and rising healthcare expenditure. Ongoing research and development activities for developing advanced microbiology-based diagnostic techniques and untapped emerging markets offering huge growth opportunities are expected to propel the market growth.

Increasing Product Launches by Key Market Players

Increasing adoption of organic growth strategies such as product launches by key market players is expected to drive the market growth over the forecast period. For instance, in October 2021, PRIORCLAVE LTD., a medical equipment company, launched New Autoclave Groups at Medica 2021. There are three core research grade laboratory autoclave groups and within each group there are several models, each offering more features and benefits than previously available standards. Priorclave’s BASE range covers “the basics”: media preparation, waste loads, and sterilizing loose instruments, open containers, and labware.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

Global clinical microbiology market growth is driven by rising prevalence of infectious diseases worldwide. Infectious diseases continue to pose a major threat to public health in both developing and developed countries. Several factors such as increasing antimicrobial resistance, aging population, lifestyle changes, environmental degradation, and international travel contributes to the spread of both common and emerging infectious pathogens. Many developing nations across Asia Pacific and Africa are witnessing a growing burden of infectious illnesses like tuberculosis, malaria, dengue, hepatitis, HIV/AIDS, and others. Changes in climate and environmental conditions Diagnosis of infectious diseases therefore assumes great importance from a public health perspective. Rising disease incidence will correspondingly drive more testing volume and demand for advanced diagnostic techniques across various healthcare settings.

To learn more about this report, request a free sample copy

Increasing product recall by regulatory authorities such as U.S. Food and Drug Administration can hamper the market growth over the forecast period. For instance, in May 2023, Becton, Dickinson and Company (BD), a medical device company, announced that the U.S. Food and Drug Administration had recalled its CD5 Series of Genesis Reusable Rigid Sterilization Container Systems, and has recommended the product to be discarded by any customers. The company stated that the products did not meet shelf-life testing requirements.

Market Opportunity – Increasing Adoption of Inorganic Growth Strategies

Increasing adoption of inorganic growth strategies such as agreements among key market players is expected to offer lucrative growth opportunities for the market growth. For instance, in December 2023, Biosero, a BICO, the bio convergence company and developer of laboratory automation solutions, announced that it had signed an agreement with a global life science company  to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects.

To learn more about this report, request a free sample copy

Product Type segment is sub-segmented into laboratory instruments, automated culture systems, and reagents. The laboratory instruments sub-segment is estimated to hold 41.9% of the market share in 2024, owing to their ability to provide reliable and accurate testing results. Laboratory instruments such as microscopes, analyzers, and autoclave systems are essential tools for clinical microbiology testing. Microscopes allow clinicians to quickly and clearly view patient samples to identify abnormalities. Analyzers automate testing procedures, thus, reducing manual labor and improving efficiency. This is particularly important as the volume of tests continues rising. Autoclave systems are critical for safely sterilizing laboratory equipment and surfaces, thus, preventing contamination. Growing complexity of diseases and testing requirements further boosts demand. Advanced instruments can detect pathogens faster and with higher sensitivity than older models and this improves diagnostics and treatment outcomes. Researchers also utilize laboratory instruments for developing new testing methods and diagnostic techniques.

Insights, By Disease Type: Bloodstream Infections Boosts Testing Needs

Disease Type segment is sub-segmented into  respiratory diseases, bloodstream infections, gastrointestinal diseases, others. Bloodstream infections sub-segment is estimated to hold 36.4% of the market share in 2024, due to their life-threatening nature and increasing incidence rates. Bloodstream infections occur when bacteria or other microbes enter the bloodstream, potentially spreading throughout the body. Without prompt diagnosis and treatment, bloodstream infections can quickly become septicemic and cause fatal sepsis. This makes rapid and accurate testing critical for patients suspected of a bloodstream infection. Clinicians aggressively test blood samples from at-risk patients to identify the culprit pathogen. A variety of microbiology lab instruments, reagents, and services are used in this targeted testing. These factors underpin heightened screening and testing requirements around bloodstream infections compared to other disease types.

Insights, By End User: Need For Non-invasive Diagnostics

End User segment is sub-segmented into hospitals, custom lab service providers, academic & research institutes. The hospitals sub-segment is estimated to hold 33.1% of the market share in 2024, reflecting their greatest needs for robust clinical microbiology diagnostics. As frontline healthcare facilities, hospitals regularly receive patients with infectious disease concerns. Medical staff are able to quickly and accurately test samples to confirm or rule out infections. This informs critical decisions around patient isolation protocols, administration of empiric antibiotics, specialist consultations, and more. Delays or errors in test results could negatively impact treatment outcomes or even lead to healthcare-associated infections. Moreover, hospitals possess onsite clinical laboratories equipped with an array of high-throughput automated instrumentation, multiple test options, and staff experienced in microbiology testing. This wide diagnostic capability means these can serve as a major diagnostic resource for providers and patients. Therefore, hospitals spearhead clinical microbiology testing demand to facilitate effective patient care and curb healthcare costs from hard-to-treat infections. Their need for advanced, customizable services and products underscores why hospitals lead as end users.

Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global clinical microbiology market and is estimated to hold 34.4% of the market share in 2024, owing to strong presence of leading product manufacturers and robust healthcare infrastructure in the region. The U.S. accounts for the largest share due to presence of most sophisticated clinical setups and growing demand for advanced microbiology diagnostic tests. Several major pharmaceutical companies headquartered in the U.S. have been investing heavily in R&D to develop novel microbiology diagnostics and testing equipment, and this leads to new product launches.

Asia Pacific region is emerging as the fastest growing market for clinical microbiology globally. Significant growth in healthcare spending by both government and private bodies has enhanced diagnostic capabilities of clinical labs in Asia. Rapidly developing economies like China and India are attracting big global players to set up manufacturing bases in these countries, ensuring easy availability of advanced products. Rising population, increasing incidence of infectious disease and growing geriatric population drives the clinical microbiology market in Asia.

Market Report Scope

Key Developments

• In May 2023, Copan Diagnostics Inc., a manufacturer of laboratory products, announced the launch of CYCLONE AUTO-PREP, a fully automated instrument for preparing pour plate total viable bacterial counts on liquid samples, with optional Smart Incubators and the use of Artificial Intelligence (AI) for automatic colony counting and colony recognition for most common bacteria of specific interest in the food protection industry
• In March 2023, bioMérieux SA, a biotechnology company, in collaboration with its partner Interscience, laboratory equipment supplier in U.S., introduced the 3P STATION, an automated system tailored to meet the specific requirements of pharmaceutical industry stakeholders. This automated system optimizes and ensures reliable reading performances and was created specially to satisfy the environmental monitoring requirements of the pharmaceutical industry
• In February 2023,bioMérieux SA launched MAESTRIA, a cutting-edge middleware designed for microbiology laboratories. With the help of this new-generation middleware, all routine activities in the microbiology lab will be managed through a single software tool.
• In May 2022, Hologic, Inc., a medical technology company, announced that it had received European CE Mark approval for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, expanding its transplant pathogen monitoring menu.

*Definition: Clinical Microbiology involves the commercialization of diagnostics tools, instruments, and consumables used for the identification and diagnosis of human microbial infections and diseases. It covers all products used in clinical microbiology laboratories to identify microorganisms like bacteria, viruses, fungi and parasites causing infections in patients for appropriate treatment and management of infectious diseases.

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Laboratory Instruments
    • Incubators
    • Gram Stainers
    • Bacterial Colony Counters
    • Autoclave Sterilizers
    • Petri Dish Fillers
  • Automated Culture Systems
    • Microbiology Analyzers
    • Microscopes
    • Molecular Diagnostic Instruments
    • Mass Spectrometers
  • Reagents
•  Disease Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Respiratory Diseases
  • Bloodstream Infections
  • Gastrointestinal Diseases
  • Others
•  End User Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospitals
  • Custom Lab Service Providers
  • Academic & Research Institutes
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Danaher
  • Abbott
  • Hologic, Inc.
  • Bruker
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Analytik Jena GmbH+Co. KG
  • Biolab Scientific
  • Reichert, Inc.
  • BIOBASE GROUP
  • Cole-Parmer Instrument Company, LLC. 
  • ESICO INTERNATIONAL
  • Isolab Laborgeräte GmbH
  • Eppendorf SE
  • Biosan
  • Beckman Coulter, Inc.
  • NuAire, Inc.